Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Incyte (INCY) Price Target Lifted to $107 at Brean Capital; 'Broad And Robust Pipeline'
April 30, 2015 12:34 PM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Incyte (NASDAQ: INCY) to $107.00 (from $84.00), citing a broad and robust pipeline.
Aschoff commented, "US Jakafi sales of $115.3 million included meaningful contribution from PV and beat consensus of $112.4 million. Ex-US Jakafi royalties of $15.7 million slightly missed consensus of $16.1 million. The 9% QoQ increase in Jakafi net sales was driven by 8% unit... More
Incyte (INCY) Misses Q1 EPS by 1c
April 30, 2015 10:03 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $159.28 million versus the consensus estimate of $155.21 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
... More